Immunoregulatory T cells in tumor immunity

Current Opinion in Immunology

Volumn 16, Issue 2, 2004, Pages 157-162

  Terabe, Masaki ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

galactosylceramide; GalCer; CTL; CTL associated antigen 4; CTLA 4; Cytotoxic T lymphocyte; DC; Dendritic cell; GITR; Glucocorticoid induced TNF receptor; GM CSF; Granulocyte macrophage colony stimulation factor; IFN ; Interferon

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; OLIGODEOXYNUCLEOTIDE; RECOMBINANT INTERLEUKIN 2;

BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER SURVIVAL; CELL ACTIVITY; COLON CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FIBROSARCOMA; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; KNOCKOUT MOUSE; LYMPHOCYTE FUNCTION; MASTOCYTOMA; MELANOMA; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, CD4; AUTOIMMUNITY; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 1542309563     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.01.010     Document Type: Review

References (74)

1. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155:1995;1151-1164.
2. + regulatory T cells control Leishmania major persistence and immunity. Nature. 420:2002;502-507.
3. + regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol. 170:2003;394-399.
4. + T cell responses. J Exp Med. 198:2003;889-901.
5. + T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol. 32:2002;1282-1291.
6. + regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med. 198:2003;259-266.
7. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 162:1999;5317-5326.
8. + immunoregulatory cells. J Immunol. 167:2001;1137-1140.
9. + T-cell responses by regulatory T cells.
10. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 193:2001;1311-1318.
11. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 193:2001;1285-1294.
12. Levings M.K., Sangregorio R., Roncarolo M.G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 193:2001;1295-1302.
13. Dieckmann D., Plottner H., Berchtold S., Berger T., Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 193:2001;1303-1310.
14. Taams L.S., Smith J., Rustin M.H., Salmon M., Poulter L.W., Akbar A.N. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 31:2001;1122-1131.
15. high regulatory cells in human peripheral blood. J Immunol. 167:2001;1245-1253.
16. + suppressor T cells: more questions than answers. Nat Rev Immunol. 2:2002;389-400.
17. •].
18. + T cells and that antagonists of GITR can inhibit the suppressive function of the cell in vitro and in vivo.
19. •].
20. •].
21. + T cells.
22. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:1999;3128-3133.
23. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:1999;5211-5218.
24. + T cells induces an anti-tumor T-cell response against shared antigens among unrelated tumors.
25. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother. 25:2002;207-217.
26. + regulatory T cells in antitumor therapy reveals alternative cytotoxic T lymphocyte responses. J. Exp. Med. 194:2001;823-832.
27. Steitz J., Bruck J., Lenz J., Knop J., Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61:2001;8643-8646.
28. Taguchi O., Takahashi T. Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease. Eur J Immunol. 26:1996;1608-1612.
29. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2:2002;1.
30. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., June C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:2001;4766-4772.
31. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother. 26:2003;85-93.
32. + T cells and disease prognosis in patients with gastrointestinal malignancies.
33. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., Drebin J.A., Strasberg S.M., Eberlein T.J., Goedegebuure P.S.et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 169:2002;2756-2761.
34. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 9:2003;606-612.
35. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., Kaiser L.R., June C.H. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 168:2002;4272-4276.
36. + regulatory T cells by antigen-processing dendritic cells. J Exp Med. 198:2003;235-247.
37. Koseki H., Imai K., Ichikawa T., Hayata I., Taniguchi M. Predominant use of a particular alpha-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int Immunol. 1:1989;557-564.
38. + thymocytes selected by MHC class I molecules. Science. 263:1994;1774-1778.
39. Fowlkes B.J., Kruisbeek A.M., Ton-That H., Weston M.A., Coligan J.E., Schwartz R.H., Pardoll D.M. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature. 329:1987;251-254.
40. Bendelac A., Rivera M.N., Park S.H., Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol. 15:1997;535-562.
41. Taniguchi M., Harada M., Kojo S., Nakayama T., Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 21:2003;483-513.
42. Kronenberg M., Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2:2002;557-568.
43. Vincent M.S., Gumperz J.E., Brenner M.B. Understanding the function of CD1-restricted T cells. Nat Immunol. 4:2003;517-523.
44. •], this study demonstrated that NKT cells retained a high level of mRNA for IL-4 and IFN-γ without the proteins and that in vivo α-GalCer treatment did not polarize NKT cells, but induced an IFN-γ response by NK cells.
45. •].
46. Wilson S.B., Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nature Reviews Immunology. 3:2003;211-222.
47. Wilson M.T., Van Kaer L. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr Pharm Des. 9:2003;201-220.
48. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology. 1:2000;515-520.
49. Ostrand-Rosenberg S., Clements V.K., Terabe M., Park J.M., Berzofsky J., Dissanayake S.K. Resistance to metastatic disease in Stat6-deficient mice requires hematopoietic and non-hematopoietic cells and is IFNγ-dependent. Journal of Immunol. 169:2002;5796-5804.
50. Moodycliffe A.M., Nghiem D., Clydesdale G., Ullrich S.E. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol. 1:2000;521-525.
51. + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol. 163:1999;184-193.
52. Terabe M., Matsui S., Park J-M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B.et al. TGF-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block CTL-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 198:2003;1741-1752 This study elucidated the downstream half of a novel immunoregulatory circuit involving NKT cells, IL-13, myeloid cells, and TGF-β which down-regulates tumor immunosurveillance and together with #48 completed the definition of this new circuit.
53. Terabe M., Park J.M., Berzofsky J.A. Role of IL-13 in negative regulation of anti-tumor immunity. Cancer Immunol and Immunotherapy. 53:2004;79-85.
54. Ostrand-Rosenberg S., Grusby M.J., Clements V.K. Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma. J Immunol. 165:2000;6015-6019.
55. Kacha A.K., Fallarino F., Markiewicz M.A., Gajewski T.F. Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6- Deficient Mice. J Immunol. 165:2000;6024-6028.
56. +) T cells established from murine tumor-infiltrating lymphocytes. J Immunol. 158:1997;4846-4854.
57. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E., Berzofsky J.A. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc Natl Acad Sci USA. 99:2002;13020-13025.
58. Sfondrini L., Besusso D., Zoia M.T., Rodolfo M., Invernizzi A.M., Taniguchi M., Nakayama T., Colombo M.P., Menard S., Balsari A. Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol. 169:2002;151-158.
59. Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:2002;629-638.
60. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 191:2000;661-668.
61. Stewart T.J., Smyth M.J., Fernando G.J., Frazer I.H., Leggatt G.R. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res. 63:2003;3058-3060.
62. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 13:2001;459-463.
63. Gillessen S., Naumov Y.N., Nieuwenhuis E.E., Exley M.A., Lee F.S., Mach N., Luster A.D., Blumberg R.S., Taniguchi M., Balk S.P.et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA. 100:2003;8874-8879.
64. Hayakawa Y., Takeda K., Yagita H., Van Kaer L., Saiki I., Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol. 166:2001;6012-6018.
65. Hammond K.J., Pellicci D.G., Poulton L.D., Naidenko O.V., Scalzo A.A., Baxter A.G., Godfrey D.I. CD1d-restricted NKT cells: an interstrain comparison. J Immunol. 167:2001;1164-1173.
66. Hansen D.S., Siomos M.A., Buckingham L., Scalzo A.A., Schofield L. Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity. 18:2003;391-402 This study showed a possible role of the NK gene complex to determine a difference in activity of NKT cells between BALB/c and C57BL/6 mice.
67. Yanagisawa K., Seino K., Ishikawa Y., Nozue M., Todoroki T., Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol. 168:2002;6494-6499.
68. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., Balk S.P., Exley M.A. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 167:2001;4046-4050.
69. + natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 63:2003;4101-4106.
70. •].
71. •] showed that Th2 polarization of NKT cells from cancer patients can be reversed towards Th1 by antigenic stimulation by DCs.
72. Fujii S., Shimizu K., Kronenberg M., Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 3:2002;867-874 This paper demonstrated that administration of α-GalCer-pulsed DC in the mouse induced a prolonged IFN-γ-producing response by NKT cells compared to that induced by free α-GalCer.
73. Seo N., Hayakawa S., Tokura Y. Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol. 12:2002;291-300.
74. + regulatory T cells suppress NKT cell functions. Cancer Res. 63:2003;4516-4520.